세계의 폴리 카테터 시장 : 삽입별, 프렌치 사이즈별, 팁별, 풍선 사이즈별, 루멘수별, 재료별, 코팅 유형별, 성별, 최종사용자별, 지역별 - 예측(-2030년)

The global Foley catheters market is projected to reach USD 1,205.0 million by 2030 from USD 931.0 million in 2025, at a CAGR of 5.3% during the forecast period.

The market for Foley catheters is primarily driven by the rising prevalence of urological disorders, urinary incontinence, and prostate-related conditions, particularly among the aging population. Additionally, increasing surgical volumes in specialties such as urology, gynecology, and general surgery are contributing to the greater use of Foley catheters in perioperative care.

The growth of healthcare infrastructure in emerging economies, along with improved access to advanced treatment options, is expanding patient reach and driving demand. Furthermore, product innovations-such as antimicrobial coatings and infection-resistant designs-are mitigating the risks of hospital-acquired infections, making the adoption of these catheters more appealing.

Despite these positive trends, patient discomfort, stigma, and a growing preference for alternative catheterization methods may restrain market growth.

By balloon type, the 5 mL balloons segment is expected to register the highest CAGR during the forecast period.

Based on balloon size, the Foley catheters market is divided into 5 mL balloons, 10 mL balloons, and other balloon sizes. The 5 mL balloons segment registered the highest CAGR during the forecast period, driven by its use in short-term catheterization and postoperative care due to its comfort and minimal bladder irritation. Its appeal to pediatric and female patients further boosts demand. To capitalize on this trend, market players should focus on developing high-quality, infection-resistant 5 mL catheters and strengthening distribution in hospitals while targeting specific patient needs.

By material, the latex Foley catheters segment holds the largest market share during the forecast period.

By material, the Foley catheters market is divided into latex, silicone, and hybrid Foley catheters. The latex Foley catheters segment leads in market share due to their availability, flexibility, and cost-effectiveness, making them popular in hospitals and clinics globally. Despite concerns about latex allergies, demand remains high because of their ease of use and affordability compared to silicone. Manufacturers can enhance safety with advanced coatings and hypoallergenic options while improving distribution in price-sensitive markets to maintain leadership in this high-demand segment.

Europe is expected to hold the largest market share during the forecast period.

The global Foley catheters market is divided into five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Europe is expected to hold the largest market share during the forecast period due to its advanced healthcare infrastructure, high spending, and an aging population susceptible to urological disorders. Key countries like Germany, France, and the UK drive demand with strong surgical volumes and established reimbursement systems. The region's focus on infection control has increased the use of coated and antimicrobial Foley catheters. Market players can capitalize on Europe's innovation-driven environment by introducing advanced technologies and enhancing collaborations with healthcare providers for sustained growth.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1 (28%), Tier 2 (39%), and Tier 3 (33%)
• By Designation: C-level Executives (26%), Director-level Executives (32%), and Others (42%)
• By Region: North America (24%), Europe (40%), Asia Pacific (33%), Latin America (2%), and the Middle East & Africa (1%)

Note 1: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.0 billion, Tier 2 = USD 1.0 billion to USD 10.0 billion, and Tier 3 = <USD 1.0 billion.

Note 2: C-level executives include CEOs, CFOs, COOs, and VPs.

Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

The players operating in the Foley catheters market include Coloplast A/S (Denmark), B. Braun SE (Germany), Becton, Dickinson and Company (US), Cardinal Health, Inc. (US), Teleflex Incorporated (US), Medtronic Plc (Ireland), Sterimed Group (India), Medline Industries, LP (US), Amsino International, Inc. (US), Bactiguard AB (US), McKesson Corporation (US), AdvaCare Pharma (US), Angiplast Private Limited (India), Ribbel International Limited (India), Optimum Medical Limited (UK), Suzhou Sunmed Co., Ltd. (China), Well Lead Medical Co., Ltd. (China), Polymed (India), HEMC (Hospital Equipment Manufacturing Company) (India), GPC Medical Ltd. (India), Hangzhou Formed Medical Devices Co., Ltd. (China), RWD Life Science Co., Ltd. (China), Advin Health Care (India), Pennine Healthcare (UK), Guangdong Baihe Medical Technology Co., Ltd. (China), and Handan FCH Medical Technology Co., Ltd. (China).

Research Coverage

This report analyzes the Foley catheters market by examining several key factors, including insertion type, French size, tip type, balloon type, number of lumens, material, coating type, gender, end user, and region. It also investigates the elements that influence market growth, such as drivers, restraints, opportunities, and challenges, while offering insights into the competitive landscape among leading market players. Furthermore, the report evaluates micromarkets by assessing their individual growth trends and forecasting the revenue of market segments across five major regions, including their respective countries.

Reasons to Buy the Report

The report will help both established companies and new or smaller firms understand the current market trends, allowing them to increase their market share. Companies that purchase the report can implement one or more of the following strategies to enhance their market presence.

This report provides insights into the following pointers:

• Analysis of key drivers (increasing prevalence of urological disorders, increasing surgical volumes and ICU admissions, rapid growth in global geriatric population, and shift toward post-acute and home-based care), restraints (patient discomfort and stigma and growing preference for alternative catheterization methods), opportunities (innovation in catheter design and material composition, development of smart Foley catheters, and increasing healthcare infrastructure in emerging markets), and challenges (high risk of catheter-associated urinary tract infections (CAUTIs) and improper insertion or maintenance of Foley catheters)
• Market Penetration: Complete knowledge of the spectrum of products presented by the major companies in the Foley catheters market
• Product Development/Innovation: Comprehensive understanding of the forthcoming trends, research and development initiatives, and product launches & approvals within the Foley catheters market
• Market Development: Complete knowledge about profitable developing regions
• Market Diversification: Exhaustive knowledge of new goods, expanding geographies, and current changes in the Foley catheters industry helps to diversify the market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Coloplast A/S (Denmark), Becton, Dickinson and Company (US), Teleflex Incorporated (US), Cardinal Health, Inc. (US), and B. Braun SE (Germany)

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY RESEARCH
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Primary sources
    • 2.1.2.2 Key data from primary sources
    • 2.1.2.3 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Approach 1: Company revenue estimation approach
    • 2.2.1.2 Approach 2: Presentations of companies and primary interviews
    • 2.2.1.3 Growth forecast
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 RESEARCH ASSUMPTIONS
  • 2.5.1 PARAMETRIC ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 FOLEY CATHETERS MARKET OVERVIEW
• 4.2 EUROPE: FOLEY CATHETERS MARKET, BY END USER AND COUNTRY (2024)
• 4.3 GEOGRAPHICAL GROWTH OPPORTUNITIES IN FOLEY CATHETERS MARKET
• 4.4 FOLEY CATHETERS MARKET: GEOGRAPHICAL MIX
• 4.5 FOLEY CATHETERS MARKET: EMERGING VS. DEVELOPED ECONOMIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing prevalence of urological disorders
    • 5.2.1.2 Increasing surgical volumes and ICU admissions
    • 5.2.1.3 Rapid growth in global geriatric population
    • 5.2.1.4 Shift toward post-acute and home-based care
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Patient discomfort and stigma
    • 5.2.2.2 Growing preference for alternative catheterization methods
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Innovation in catheter design and material composition
    • 5.2.3.2 Development of smart Foley catheters
    • 5.2.3.3 Increasing healthcare infrastructure in emerging markets
  • 5.2.4 CHALLENGES
    • 5.2.4.1 High risk of catheter-associated urinary tract infections (CAUTIs)
    • 5.2.4.2 Improper insertion or maintenance of Foley catheters
• 5.3 PRICING ANALYSIS
  • 5.3.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYERS, 2022-2024
  • 5.3.2 AVERAGE SELLING PRICE TREND, BY REGION 2022-2024
  • 5.3.3 AVERAGE SELLING PRICE TREND, BY TIP TYPE, 2022-2024
  • 5.3.4 AVERAGE SELLING PRICE TREND, BY COATING TYPE, 2022-2024
• 5.4 VALUE CHAIN ANALYSIS
  • 5.4.1 RESEARCH & DEVELOPMENT
  • 5.4.2 RAW MATERIAL SUPPLIERS
  • 5.4.3 MANUFACTURING
  • 5.4.4 DISTRIBUTION
  • 5.4.5 MARKETING & SALES
  • 5.4.6 POST-SALES SERVICES
• 5.5 SUPPLY CHAIN ANALYSIS
  • 5.5.1 PROMINENT COMPANIES
  • 5.5.2 SMALL & MEDIUM-SIZED ENTERPRISES
  • 5.5.3 END USERS
• 5.6 ECOSYSTEM ANALYSIS
• 5.7 TECHNOLOGY ANALYSIS
  • 5.7.1 KEY TECHNOLOGIES
    • 5.7.1.1 Antimicrobial coating technologies
    • 5.7.1.2 Hydrophilic technology
  • 5.7.2 COMPLEMENTARY TECHNOLOGIES
    • 5.7.2.1 Smart catheters
    • 5.7.2.2 Catheter securement devices
• 5.8 PORTER'S FIVE FORCES ANALYSIS
  • 5.8.1 THREAT OF NEW ENTRANTS
  • 5.8.2 THREAT OF SUBSTITUTES
  • 5.8.3 BARGAINING POWER OF SUPPLIERS
  • 5.8.4 BARGAINING POWER OF BUYERS
  • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.9 REGULATORY ANALYSIS
  • 5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.9.2 REGULATORY LANDSCAPE
    • 5.9.2.1 North America
      • 5.9.2.1.1 US
      • 5.9.2.1.2 Canada
    • 5.9.2.2 Europe
      • 5.9.2.2.1 Germany
      • 5.9.2.2.2 UK
      • 5.9.2.2.3 France
      • 5.9.2.2.4 Italy
      • 5.9.2.2.5 Spain
    • 5.9.2.3 Asia Pacific
      • 5.9.2.3.1 China
      • 5.9.2.3.2 Japan
      • 5.9.2.3.3 India
    • 5.9.2.4 Latin America
      • 5.9.2.4.1 Brazil
      • 5.9.2.4.2 Mexico
    • 5.9.2.5 Middle East
    • 5.9.2.6 Africa
• 5.10 PATENT ANALYSIS
• 5.11 TRADE ANALYSIS
  • 5.11.1 IMPORT DATA FOR HS CODE 901839
  • 5.11.2 EXPORT DATA FOR HS CODE 901839
• 5.12 KEY CONFERENCES & EVENTS, 2025-2026
• 5.13 CASE STUDY ANALYSIS
  • 5.13.1 CASE STUDY 1: APPROPRIATE USE OF INDWELLING URINARY CATHETERS REDUCES RISK OF CAUTI
  • 5.13.2 CASE STUDY 2: DECREASE IN FOLEY CATHETER UTILIZATION RATES IMPROVES PATIENT CARE IN AN INTENSIVE CORONARY CARE UNIT
• 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.15 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.15.2 BUYING CRITERIA
• 5.16 INVESTMENT & FUNDING SCENARIO
• 5.17 IMPACT OF AI/GENERATIVE AI ON FOLEY CATHETERS MARKET
  • 5.17.1 INTRODUCTION
  • 5.17.2 POTENTIAL OF AI IN FOLEY CATHETERS MARKET
  • 5.17.3 AI USE CASES
  • 5.17.4 KEY COMPANIES IMPLEMENTING AI
  • 5.17.5 FUTURE OF GENERATIVE AI IN FOLEY CATHETERS MARKET
• 5.18 IMPACT OF 2025 US TARIFFS ON FOLEY CATHETERS MARKET
  • 5.18.1 INTRODUCTION
  • 5.18.2 KEY TARIFF RATES
  • 5.18.3 IMPACT OF TARIFFS ON PRICING
  • 5.18.4 IMPACT ON REGIONS
    • 5.18.4.1 North America
    • 5.18.4.2 Europe
    • 5.18.4.3 Asia Pacific
  • 5.18.5 END-USER INDUSTRY IMPACT

6 FOLEY CATHETERS MARKET, BY INSERTION TYPE

• 6.1 INTRODUCTION
• 6.2 URETHRAL CATHETERS
  • 6.2.1 GROWING BURDEN OF UROLOGIC CANCERS TO DRIVE MARKET GROWTH
• 6.3 SUPRAPUBIC CATHETERS
  • 6.3.1 REDUCED INCIDENCE OF CATHETER-ASSOCIATED URINARY TRACT INFECTIONS (CAUTIS) TO DRIVE DEMAND

7 FOLEY CATHETERS MARKET, BY FRENCH SIZE

• 7.1 INTRODUCTION
• 7.2 12FR AND BELOW
  • 7.2.1 INCREASING FOCUS ON PEDIATRIC UROLOGY AND NEONATAL INTENSIVE CARE TO DRIVE MARKET GROWTH
• 7.3 14FR
  • 7.3.1 INCREASING BURDEN OF CHRONIC DISEASES TO SUPPORT MARKET GROWTH
• 7.4 16FR
  • 7.4.1 GROWING GERIATRIC POPULATION AND INCREASING INCIDENCE OF CHRONIC CONDITIONS TO BOOST MARKET
• 7.5 18FR
  • 7.5.1 GROWING PREVALENCE OF URINARY INCONTINENCE TO BOOST MARKET
• 7.6 20FR AND ABOVE
  • 7.6.1 RISING INCIDENCE OF GENITOURINARY MALIGNANCIES TO DRIVE MARKET GROWTH

8 FOLEY CATHETERS MARKET, BY TIP TYPE

• 8.1 INTRODUCTION
• 8.2 STRAIGHT-TIPPED CATHETERS
  • 8.2.1 INCREASING INCIDENCE OF POSTOPERATIVE URINARY RETENTION TO PROPEL DEMAND
• 8.3 COUDE-TIPPED CATHETERS
  • 8.3.1 GROWING PREVALENCE OF BENIGN PROSTATIC HYPERPLASIA (BHP) TO SUPPORT MARKET GROWTH
• 8.4 OTHER-TIPPED CATHETERS

9 FOLEY CATHETERS MARKET, BY BALLOON SIZE

• 9.1 INTRODUCTION
• 9.2 5 ML BALLOONS
  • 9.2.1 PROVISION OF SECURE BLADDER ANCHORAGE TO DRIVE DEMAND
• 9.3 10 ML BALLOONS
  • 9.3.1 AGING POPULATION TO FUEL DEMAND FOR 10 ML BALLOONS
• 9.4 OTHER BALLOON SIZES

10 FOLEY CATHETERS MARKET, BY LUMEN NUMBER

• 10.1 INTRODUCTION
• 10.2 2-WAY
  • 10.2.1 INCREASING INCIDENCE OF NEUROGENIC BLADDER DISORDERS TO DRIVE DEMAND FOR 2-WAY CATHETERS
• 10.3 3-WAY & 4-WAY
  • 10.3.1 INCREASING INCIDENCE OF BLADDER CANCER TO DRIVE GROWTH

11 FOLEY CATHETERS MARKET, BY MATERIAL

• 11.1 INTRODUCTION
• 11.2 LATEX FOLEY CATHETERS
  • 11.2.1 COST-EFFECTIVENESS OF LATEX TO PROPEL DEMAND
• 11.3 SILICONE FOLEY CATHETERS
  • 11.3.1 REDUCED RISK OF ALLERGIC REACTIONS ASSOCIATED WITH SILICONE CATHETERS TO SUPPORT MARKET GROWTH
• 11.4 HYBRID FOLEY CATHETERS
  • 11.4.1 ADVANCEMENTS IN COATING TECHNOLOGIES TO DRIVE ADOPTION

12 FOLEY CATHETERS MARKET, BY COATING TYPE

• 12.1 INTRODUCTION
• 12.2 ANTIMICROBIAL-COATED FOLEY CATHETERS
  • 12.2.1 HIGH INCIDENCE OF CATHETER-ASSOCIATED URINARY TRACT INFECTIONS TO DRIVE DEMAND
• 12.3 HYDROPHILIC OR LUBRICATION-COATED FOLEY CATHETERS
  • 12.3.1 INCREASING FOCUS ON PATIENT SAFETY AND COMFORT TO SUPPORT MARKET GROWTH
• 12.4 UNCOATED FOLEY CATHETERS
  • 12.4.1 INCREASING DEMAND DUE TO AFFORDABILITY AND ACCESSIBILITY TO DRIVE MARKET GROWTH

13 FOLEY CATHETERS MARKET, BY GENDER

• 13.1 INTRODUCTION
• 13.2 MALES
  • 13.2.1 INCREASING INCIDENCE OF KIDNEY, PROSTATE, AND BLADDER CANCERS AMONG MEN TO BOOST MARKET GROWTH
• 13.3 FEMALES
  • 13.3.1 INCREASING PREVALENCE OF URINARY INCONTINENCE TO DRIVE MARKET GROWTH

14 FOLEY CATHETERS MARKET, BY END USER

• 14.1 INTRODUCTION
• 14.2 HOSPITALS & ASCS
  • 14.2.1 HIGH VOLUME OF SURGICAL PROCEDURES TO DRIVE DEMAND
• 14.3 LONG-TERM CARE FACILITIES
  • 14.3.1 EXPANSION OF LONG-TERM CARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
• 14.4 OTHER END USERS

15 FOLEY CATHETERS MARKET, BY REGION

• 15.1 INTRODUCTION
• 15.2 EUROPE
  • 15.2.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 15.2.2 GERMANY
    • 15.2.2.1 Growing incidence of urinary incontinence to propel demand
  • 15.2.3 UK
    • 15.2.3.1 Well-established healthcare infrastructure to accelerate demand
  • 15.2.4 FRANCE
    • 15.2.4.1 Large target population to support market growth
  • 15.2.5 ITALY
    • 15.2.5.1 Increasing prevalence of urological conditions to drive the demand
  • 15.2.6 SPAIN
    • 15.2.6.1 Rising prevalence of chronic disorders to drive market growth
  • 15.2.7 REST OF EUROPE
• 15.3 NORTH AMERICA
  • 15.3.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 15.3.2 US
    • 15.3.2.1 Rising prevalence of conditions such as benign prostatic hyperplasia (BPH) to drive demand
  • 15.3.3 CANADA
    • 15.3.3.1 Substantial investment in healthcare infrastructure to drive demand
• 15.4 ASIA PACIFIC
  • 15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 15.4.2 CHINA
    • 15.4.2.1 Rapidly increasing elderly population to boost demand
  • 15.4.3 JAPAN
    • 15.4.3.1 Presence of established healthcare system and favorable reimbursements to drive market
  • 15.4.4 INDIA
    • 15.4.4.1 Rising incidence of cancers to drive demand
  • 15.4.5 REST OF ASIA PACIFIC
• 15.5 LATIN AMERICA
  • 15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 15.5.2 BRAZIL
    • 15.5.2.1 Rising prevalence of cancer to drive demand
  • 15.5.3 MEXICO
    • 15.5.3.1 Rising geriatric population to drive demand
  • 15.5.4 REST OF LATIN AMERICA
• 15.6 MIDDLE EAST & AFRICA
  • 15.6.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
  • 15.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

16 COMPETITIVE LANDSCAPE

• 16.1 OVERVIEW
• 16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN FOLEY CATHETERS MARKET
• 16.3 REVENUE ANALYSIS, 2022-2024
• 16.4 MARKET SHARE ANALYSIS, 2024
• 16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 16.5.1 STARS
  • 16.5.2 EMERGING LEADERS
  • 16.5.3 PERVASIVE PLAYERS
  • 16.5.4 PARTICIPANTS
  • 16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 16.5.5.1 Company footprint
    • 16.5.5.2 Region footprint
    • 16.5.5.3 Insertion type footprint
    • 16.5.5.4 Coating type footprint
    • 16.5.5.5 End-user footprint
• 16.6 COMPANY EVALUATION MATRIX: SMES/STARTUPS, 2024
  • 16.6.1 PROGRESSIVE COMPANIES
  • 16.6.2 RESPONSIVE COMPANIES
  • 16.6.3 DYNAMIC COMPANIES
  • 16.6.4 STARTING BLOCKS
  • 16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 16.6.5.1 Detailed list of key startups/SMEs
    • 16.6.5.2 Competitive benchmarking of key emerging players/startups
• 16.7 COMPANY VALUATION & FINANCIAL METRICS
• 16.8 BRAND/PRODUCT COMPARISON
• 16.9 COMPETITIVE SCENARIO
  • 16.9.1 PRODUCT LAUNCHES & APPROVALS
  • 16.9.2 DEALS
  • 16.9.3 EXPANSIONS

17 COMPANY PROFILES

• 17.1 KEY PLAYERS
  • 17.1.1 COLOPLAST A/S
    • 17.1.1.1 Business overview
    • 17.1.1.2 Products offered
    • 17.1.1.3 Recent developments
      • 17.1.1.3.1 Expansions
    • 17.1.1.4 MnM view
      • 17.1.1.4.1 Key strengths
      • 17.1.1.4.2 Strategic choices
      • 17.1.1.4.3 Weaknesses & competitive threats
  • 17.1.2 BECTON, DICKINSON AND COMPANY
    • 17.1.2.1 Business overview
    • 17.1.2.2 Products offered
    • 17.1.2.3 Recent developments
      • 17.1.2.3.1 Deals
    • 17.1.2.4 MnM view
      • 17.1.2.4.1 Key strengths
      • 17.1.2.4.2 Strategic choices
      • 17.1.2.4.3 Weaknesses & competitive threats
  • 17.1.3 TELEFLEX INCORPORATED
    • 17.1.3.1 Business overview
    • 17.1.3.2 Products offered
    • 17.1.3.3 MnM view
      • 17.1.3.3.1 Key strengths
      • 17.1.3.3.2 Strategic choices
      • 17.1.3.3.3 Weaknesses & competitive threats
  • 17.1.4 CARDINAL HEALTH, INC.
    • 17.1.4.1 Business overview
    • 17.1.4.2 Products offered
    • 17.1.4.3 Recent developments
      • 17.1.4.3.1 Expansions
    • 17.1.4.4 MnM view
      • 17.1.4.4.1 Key strengths
      • 17.1.4.4.2 Strategic choices
      • 17.1.4.4.3 Weaknesses & competitive threats
  • 17.1.5 B. BRAUN SE
    • 17.1.5.1 Business overview
    • 17.1.5.2 Products offered
    • 17.1.5.3 MnM view
      • 17.1.5.3.1 Key strengths
      • 17.1.5.3.2 Strategic choices
      • 17.1.5.3.3 Weaknesses & competitive threats
  • 17.1.6 MEDLINE INDUSTRIES, LP
    • 17.1.6.1 Business overview
    • 17.1.6.2 Products offered
    • 17.1.6.3 Recent developments
      • 17.1.6.3.1 Deals
      • 17.1.6.3.2 Expansions
  • 17.1.7 MEDTRONIC PLC
    • 17.1.7.1 Business overview
    • 17.1.7.2 Products offered
  • 17.1.8 STERIMED GROUP
    • 17.1.8.1 Business overview
    • 17.1.8.2 Products offered
  • 17.1.9 AMSINO INTERNATIONAL, INC.
    • 17.1.9.1 Business overview
    • 17.1.9.2 Products offered
    • 17.1.9.3 Recent developments
      • 17.1.9.3.1 Product launches
      • 17.1.9.3.2 Expansions
  • 17.1.10 BACTIGUARD AB
    • 17.1.10.1 Business overview
    • 17.1.10.2 Products offered
    • 17.1.10.3 Recent developments
      • 17.1.10.3.1 Product approvals
  • 17.1.11 MCKESSON CORPORATION
    • 17.1.11.1 Business overview
    • 17.1.11.2 Products offered
• 17.2 OTHER PLAYERS
  • 17.2.1 ADVACARE PHARMA
  • 17.2.2 ANGIPLAST PRIVATE LIMITED
  • 17.2.3 OPTIMUM MEDICAL LIMITED
  • 17.2.4 SUZHOU SUNMED CO., LTD.
  • 17.2.5 WELL LEAD MEDICAL CO., LTD.
  • 17.2.6 POLYMED
  • 17.2.7 HEMC (HOSPITAL EQUIPMENT MANUFACTURING COMPANY)
  • 17.2.8 HANGZHOU FORMED MEDICAL DEVICES CO., LTD.
  • 17.2.9 RWD LIFE SCIENCE CO., LTD.
  • 17.2.10 PENNINE HEALTHCARE
  • 17.2.11 GUANGDONG BAIHE MEDICAL TECHNOLOGY CO., LTD.
  • 17.2.12 GPC MEDICAL LTD.
  • 17.2.13 ADVIN HEALTH CARE
  • 17.2.14 RIBBEL INTERNATIONAL LTD.
  • 17.2.15 HANDAN FCH MEDICAL TECHNOLOGY CO., LTD.

18 APPENDIX

• 18.1 DISCUSSION GUIDE
• 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 18.3 CUSTOMIZATION OPTIONS
• 18.4 RELATED REPORTS
• 18.5 AUTHOR DETAILS